EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Immunophenotype-guided interpretable radiomics model for predicting neoadjuvant anti-PD-1 response in stage III–IV d-MMR/MSI-H colorectal cancer

Yiwen Zhang, Xuan Zhang, Xi Zhong, Liebin Huang, Wenjing Jiang, Caixia Zhang, Lizhu Liu, Ruimin You, Yanli Li, Xiaoping Yi, Zaiyi Liu, Xiaobo Chen und 1 weitere

Journal for ImmunoTherapy of Cancer · 2025

DOI: 10.1136/jitc-2025-011569 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2025. Verfasst von Yiwen Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, The Third Affiliated Hospital of Kunming Medical University,Yunnan Cancer Hospital,Peking University Cancer Hospital Yunna…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Neoadjuvant Therapy, Immunophenotyping, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the Innovative Research Team of Yunnan Province, the First-Class Discipline Team of Kunming Medical University, the National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Neoadjuvant immunotherapy significantly improves the pathological complete response (pCR) rate in colorectal cancer (CRC). However, the lack of reliable tools to accurately identify responders remains a key barrier to its widespread clinical adoption. This study aimed to develop an interpretable radiomics model guided by immunophenotypes to predict response to preoperative immunotherapy in CRC, with the goal of enabling more precise and personalized treatment strategies.

Methods

First, we retrospectively collected 108 patients with CRC from the center who underwent preoperative CT and RNA sequencing. Immunophenotypes were characterized through unsupervised clustering of tumor-infiltrating immune cells at RNA level, with subsequent validation by CD3 and CD8 spatial distributions at immunohistochemical (IHC) level. Furthermore, patients from center II (n=19) and center III (n=22) receiving neoadjuvant immunotherapy were assigned to training and validation cohorts. Through a two-stage selection process, immunophenotype-associated radiomic features were initially identified, followed by immunotherapy response-related radiomics features that were further identified. Eventually, an interpretable immunotherapy response prediction model was developed by integrating a decision tree algorithm with SHapley Additive exPlanations (SHAP) analysis.

Results

Two immunophenotypes (immune-hot and immune-cold) were identified, compared with the immune-cold, the former exhibited more abundant RNA-based immune cell infiltration and higher densities of CD3 and CD8 T cells in both the core tumor and invasive margin areas. A decision tree model integrating three key radiomic features achieved an area under the curve of 0.904 (95% CI: 0.679 to 1.000) in an independent validation cohort. SHAP analysis identified higher large dependence emphasis and lower variance as potential predictors of pCR, which quantified the homogeneity of the tumors.

Conclusion

Two immunophenotypes were constructed and identified at both bulk RNA level and IHC level. An interpretable and accurate radiomics model was constructed to guide personalized immunotherapy strategies in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsNeoadjuvant TherapyImmunophenotypingImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorHumansFemaleMaleMiddle AgedRetrospective StudiesAgedNeoplasm StagingLymphocytes, Tumor-InfiltratingRadiomics

Stichwörter der Autor:innen

Colorectal CancerImmunotherapy

Substanzen

Immune Checkpoint InhibitorsProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Department of Radiology, The Third Affiliated Hospital of Kunming Medical University,Yunnan Cancer Hospital,Peking University Cancer Hospital Yunnan, Kunming, Yunnan, China.
  • Faculty of Life science and Technology, Kunming University of Science and Technology, Kunming, Yunnan, China.
  • The Afiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, China.
  • Department of Colorectal surgery, The Third Affiliated Hospital of Kunming Medical University,Yunnan Cancer Hospital,Peking University Cancer Hospital Yunnan, Kunming, Yunnan, China.
  • Department of Medical Imaging, Guangzhou Medical University Affiliated Cancer Hospital, Guangzhou, Guangdong, China.
  • Department of Radiology, Jiangmen Central Hospital, Jiangmen, Guangdong, China.

Förderung

  • the Innovative Research Team of Yunnan Province
  • the First-Class Discipline Team of Kunming Medical University
  • the National Natural Science Foundation of China
  • the Yunnan Basic Research Project
  • Kunming Medical University University-Level Innovation Team
  • Yunnan Provincial Science and Technology Department - Kunming Medical University Basic Research Joint Special Outstanding Youth Cultivation Project

Zitieren

APA

Zhang, Y., Zhang, X., Zhong, X., Huang, L., Jiang, W., Zhang, C., Liu, L., You, R., Li, Y., Yi, X., Liu, Z., Chen, X., & Li, Z. (2025). Immunophenotype-guided interpretable radiomics model for predicting neoadjuvant anti-PD-1 response in stage III–IV d-MMR/MSI-H colorectal cancer. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-011569

Vancouver

Zhang Y, Zhang X, Zhong X, Huang L, Jiang W, Zhang C, et al. Immunophenotype-guided interpretable radiomics model for predicting neoadjuvant anti-PD-1 response in stage III–IV d-MMR/MSI-H colorectal cancer. Journal for ImmunoTherapy of Cancer. 2025. doi:10.1136/jitc-2025-011569

BibTeX
@article{Zhang2025,
  author = {Zhang, Yiwen and Zhang, Xuan and Zhong, Xi and Huang, Liebin and Jiang, Wenjing and Zhang, Caixia and Liu, Lizhu and You, Ruimin and Li, Yanli and Yi, Xiaoping and Liu, Zaiyi and Chen, Xiaobo and Li, Zhenhui},
  title = {Immunophenotype-guided interpretable radiomics model for predicting neoadjuvant anti-PD-1 response in stage III–IV d-MMR/MSI-H colorectal cancer},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  doi = {10.1136/jitc-2025-011569}
}
Kostenlos starten →